Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 74 for:    Paraneoplastic Syndromes

Studies of Neurological Paraneoplastic Syndromes

This study has been completed.
National Institutes of Health (NIH)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 21, 2007
Last updated: March 27, 2009
Last verified: March 2009
This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Paraneoplastic Neurologic Degenerations (PNDs)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Studies of Neurological Paraneoplastic Syndromes

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Increase understanding of PNDS [ Time Frame: Ongoing ]

Biospecimen Retention:   Samples With DNA
blood and/or spinal fluid

Enrollment: 51
Study Start Date: April 1988
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
One cohort group of patient with PNDS or suspected PNDS

Detailed Description:

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.

Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:

  • analyzing for autoantibodies in serum and cerebral spinal fluid
  • analyzing for antigen specificity and for antigens in cancer tissue
  • comparing PND autoantibodies with those in cancer patients but no PND
  • comparing PND autoantibodies with those in PND patients but no cancer
  • studying the immune performance of patients with PNDs

As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients are selected from severals clinics within Memorial Sloan-Kettering Cancer Cetner

Inclusion Criteria:

  • All adults are potentially eligible.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00587106

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)
Principal Investigator: Jerome Posner, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Jerome Posner, MD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00587106     History of Changes
Other Study ID Numbers: 88-044
Study First Received: December 21, 2007
Last Updated: March 27, 2009

Additional relevant MeSH terms:
Paraneoplastic Syndromes
Neoplasms processed this record on May 25, 2017